Scientific Presentation | 4DMT - Part 3

Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration

July 28, 2023/in Scientific Presentation/by David Anderson

AAV mediated gene therapy for cystic fibrosis: Interim results from a Phase 1/2 clinical trial

June 7, 2023/in Scientific Presentation/by Erik Allison

AAV-Mediated Gene Therapy for Cystic Fibrosis (4D 710)

May 17, 2023/in Scientific Presentation/by David Anderson

A Phase 1/2 Clinical Trial Evaluating 4D-150, a Dual-transgene Intravitreal Gene Therapy in Patients with Wet Age-Related Macular Degeneration: Interim Results

April 26, 2023/in Scientific Presentation/by David Anderson

Update on AAV-mediated CFTR gene delivery programme (4D-710)

March 13, 2023/in Scientific Presentation/by Erik Allison

Plenary 2: Novel CF Therapeutics & Clinical Trial Strategy to Accelerate Our Mission

March 13, 2023/in Scientific Presentation/by Erik Allison

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Fabry Disease

March 13, 2023/in Scientific Presentation/by Erik Allison

A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non-Human Primates

March 13, 2023/in Scientific Presentation/by Erik Allison

A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates

March 13, 2023/in Scientific Presentation/by Erik Allison

Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease

March 13, 2023/in Scientific Presentation/by Erik Allison